Journal
ANNALS OF THE AMERICAN THORACIC SOCIETY
Volume 15, Issue -, Pages S192-S197Publisher
AMER THORACIC SOC
DOI: 10.1513/AnnalsATS.201802-144AW
Keywords
IPF; MUC5B; idiopathic pulmonary fibrosis
Categories
Funding
- National Heart, Lung, and Blood Institute [UH2/3-HL123442, R01-HL097163, R21/R33-HL120770, P01-HL092870]
- Department of Defense [W81XWH-17-1-0597]
Ask authors/readers for more resources
Idiopathic pulmonary fibrosis (IPF) is localized to the lung, is characterized by a pattern of heterogeneous, subpleural patches of fibrotic, remodeled lung, and is associated with a median survival of 3-5 years after diagnosis. A common gain- of- function MUC5B promoter variant, rs35705950, is the strongest risk factor (genetic and otherwise), accounting for at least 30% of the total risk of developing IPF. The MUC5B promoter variant can be used to identify individuals in the preclinical phase of this progressive disease, and, in the IPF lung, we have found that MUC5B is specifically overexpressed in bronchoalveolar epithelium. Thus, MUC5B represents a key molecule to understand the mechanisms that appear to initiate the fibroproliferative process in the bronchoalveolar epithelium. Moreover, focusing on MUC5B may provide a unique opportunity to define the early molecular events that lead to, and potentially prevent, the development of IPF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available